Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines

    Publikation: Bidrag til tidsskriftLederpeer review

  2. Deformable image registration uncertainty for inter-fractional dose accumulation of lung cancer proton therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Outcome following local excision of T1 anal cancers-a systematic review

    Publikation: Bidrag til tidsskriftReviewpeer review

  4. Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Udredning og behandling af analcancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anna Cecilie Lefèvre
  • Camilla Kronborg
  • Brita Singers Sørensen
  • Søren Rasmus Palmelund Krag
  • Eva Serup-Hansen
  • Karen-Lise Garm Spindler
Vis graf over relationer

BACKGROUND: Measuring circulating-free-deoxyribonucleic-acid (cfDNA) has created a new framework for personalized treatment in oncology. The aim of this study was to analyze the relation between cfDNA and risk factors and outcome in squamous cell carcinoma of the anus (SCCA).

METHODS: Patients treated with radiotherapy for localized SCCA were included in Aarhus, Denmark from 2016 to 2019. Serum samples from baseline, during and after therapy, were measured for the level of cfDNA in copies per mL by a direct fluorescent assay.

RESULTS: Eighty patients were included. Samples were available at baseline (n = 73) mid-therapy (n = 74), end-therapy (n = 67) and one-year follow-up (1Y) (n = 29). P16-positivity was found in 89% (n = 55). The median level of cfDNA was higher for P16 negative tumors (1.48) compared with the P16 positive tumors (0.90, P = 0.04). Data showed a correlation between baseline cfDNA levels and Gross Tumor Volume (R2 = 0.13, P < 0.01), and increasing levels with increasing T-stage (T1 = 0.80, T2 = 0.94, T3 = 1.11, T4 = 1.3). Higher cfDNA levels were observed in patients with poor performance status (P < 0.01). The cfDNA level decreased from baseline to mid-therapy (0.92-0.78, P < 0.01) and from baseline to 1Y (0.92-0.71, P < 0.01). Baseline levels for patients with treatment failure (n = 8) were above the 25th percentile (p = 0.05) which translates into difference in disease free survival.

CONCLUSION: Results indicate an association between baseline cfDNA levels and risk factors in SCCA and a low baseline level correlates to lower risk of treatment failure. Findings contribute with new knowledge of the biological role of cfDNA in SCCA and holds potential knowledge for personalized treatment of SCCA.

OriginalsprogEngelsk
TidsskriftRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind150
Sider (fra-til)211-216
Antal sider6
ISSN0167-8140
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 61913731